SMMT
Price
$28.67
Change
+$1.10 (+3.99%)
Updated
Jul 25 closing price
Capitalization
21.29B
10 days until earnings call
VBIZF
Price
$0.19
Change
-$0.01 (-5.00%)
Updated
Jul 14 closing price
Capitalization
447.38M
Interact to see
Advertisement

SMMT vs VBIZF

Header iconSMMT vs VBIZF Comparison
Open Charts SMMT vs VBIZFBanner chart's image
Summit Therapeutics
Price$28.67
Change+$1.10 (+3.99%)
Volume$1.79M
Capitalization21.29B
Viva Biotech Holdings
Price$0.19
Change-$0.01 (-5.00%)
Volume$3K
Capitalization447.38M
SMMT vs VBIZF Comparison Chart in %
Loading...
SMMT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VBIZF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
SMMT vs. VBIZF commentary
Jul 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is SMMT is a StrongBuy and VBIZF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 27, 2025
Stock price -- (SMMT: $28.67 vs. VBIZF: $0.19)
Brand notoriety: SMMT and VBIZF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: SMMT: 41% vs. VBIZF: 144%
Market capitalization -- SMMT: $21.29B vs. VBIZF: $447.38M
SMMT [@Biotechnology] is valued at $21.29B. VBIZF’s [@Biotechnology] market capitalization is $447.38M. The market cap for tickers in the [@Biotechnology] industry ranges from $313.33B to $0. The average market capitalization across the [@Biotechnology] industry is $2.57B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

SMMT’s FA Score shows that 2 FA rating(s) are green whileVBIZF’s FA Score has 1 green FA rating(s).

  • SMMT’s FA Score: 2 green, 3 red.
  • VBIZF’s FA Score: 1 green, 4 red.
According to our system of comparison, SMMT is a better buy in the long-term than VBIZF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

SMMT’s TA Score shows that 6 TA indicator(s) are bullish while VBIZF’s TA Score has 3 bullish TA indicator(s).

  • SMMT’s TA Score: 6 bullish, 4 bearish.
  • VBIZF’s TA Score: 3 bullish, 3 bearish.
According to our system of comparison, SMMT is a better buy in the short-term than VBIZF.

Price Growth

SMMT (@Biotechnology) experienced а +9.43% price change this week, while VBIZF (@Biotechnology) price change was 0.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.62%. For the same industry, the average monthly price growth was +17.39%, and the average quarterly price growth was +28.36%.

Reported Earning Dates

SMMT is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (+7.62% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SMMT($21.3B) has a higher market cap than VBIZF($447M). SMMT has higher P/E ratio than VBIZF: SMMT (26.36) vs VBIZF (22.56). VBIZF YTD gains are higher at: 166.573 vs. SMMT (60.661).
SMMTVBIZFSMMT / VBIZF
Capitalization21.3B447M4,765%
EBITDA-235.08MN/A-
Gain YTD60.661166.57336%
P/E Ratio26.3622.56117%
Revenue0N/A-
Total Cash361MN/A-
Total Debt6.45MN/A-
FUNDAMENTALS RATINGS
SMMT vs VBIZF: Fundamental Ratings
SMMT
VBIZF
OUTLOOK RATING
1..100
9092
VALUATION
overvalued / fair valued / undervalued
1..100
95
Overvalued
3
Undervalued
PROFIT vs RISK RATING
1..100
32100
SMR RATING
1..100
9877
PRICE GROWTH RATING
1..100
3738
P/E GROWTH RATING
1..100
991
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

VBIZF's Valuation (3) in the null industry is significantly better than the same rating for SMMT (95) in the Biotechnology industry. This means that VBIZF’s stock grew significantly faster than SMMT’s over the last 12 months.

SMMT's Profit vs Risk Rating (32) in the Biotechnology industry is significantly better than the same rating for VBIZF (100) in the null industry. This means that SMMT’s stock grew significantly faster than VBIZF’s over the last 12 months.

VBIZF's SMR Rating (77) in the null industry is in the same range as SMMT (98) in the Biotechnology industry. This means that VBIZF’s stock grew similarly to SMMT’s over the last 12 months.

SMMT's Price Growth Rating (37) in the Biotechnology industry is in the same range as VBIZF (38) in the null industry. This means that SMMT’s stock grew similarly to VBIZF’s over the last 12 months.

SMMT's P/E Growth Rating (9) in the Biotechnology industry is significantly better than the same rating for VBIZF (91) in the null industry. This means that SMMT’s stock grew significantly faster than VBIZF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
SMMTVBIZF
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
59%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
Momentum
ODDS (%)
Bullish Trend 2 days ago
88%
Bearish Trend 2 days ago
81%
MACD
ODDS (%)
Bullish Trend 3 days ago
90%
Bullish Trend 2 days ago
57%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
50%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
59%
Advances
ODDS (%)
Bullish Trend 4 days ago
85%
N/A
Declines
ODDS (%)
Bearish Trend 9 days ago
81%
N/A
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
84%
N/A
Aroon
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
41%
View a ticker or compare two or three
Interact to see
Advertisement
SMMT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VBIZF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
DGOYX44.180.08
+0.18%
Davis Opportunity Y
IGNYX17.41N/A
N/A
Macquarie Natural Resources Y
GLPRX34.18N/A
N/A
Goldman Sachs MLP Energy Infras R
ATHDX31.37N/A
N/A
American Century Heritage R6
ESAGX12.13N/A
N/A
Ashmore Emerging Markets Equity ESG A